Engineered skin substitute(Lonza Group AG)(Engineered skin substitute(Lonza Group AG))

概要

基本信息

药物类型

生物药

别名

Cultured skin substitute、ESS-W、Engineered skin substitute

+ [2]

靶点-

作用方式-

作用机制-

治疗领域

其他疾病

在研适应症-

非在研适应症

烧伤

原研机构

Lonza Group AG

在研机构-

非在研机构

Amarantus Bioscience Holdings, Inc.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Engineered skin substitute(Lonza Group AG) 相关的临床试验

NCT01655407

/ Unknown status临床2期

Evaluation of Autologous Engineered Skin Substitute (ESS-W) Compared to Meshed, Split-Thickness Autograft (AG) for Treatment of Deep Partial- and Full-Thickness Thermal Burn Wounds in Adult Patients

The purpose of this research study is to test how well the investigational treatment, Engineered Skin Substitutes (ESS-W), works for covering and treating burn wounds.
The areas of the body that are treated with ESS-W will be compared to similar areas treated with the patient's own skin (split-thickness skin autograft (AG)). A skin autograft (AG) will be performed by taking healthy skin from one area of the body and placing it on the burned area.

开始日期2016-09-01

申办/合作机构

Amarantus Bioscience Holdings, Inc.

[+1]

100 项与 Engineered skin substitute(Lonza Group AG) 相关的临床结果

登录后查看更多信息

100 项与 Engineered skin substitute(Lonza Group AG) 相关的转化医学

登录后查看更多信息

100 项与 Engineered skin substitute(Lonza Group AG) 相关的专利（医药）

登录后查看更多信息

100 项与 Engineered skin substitute(Lonza Group AG) 相关的药物交易

登录后查看更多信息